NaPro receives paclitaxel administration patent
NaPro BioTherapeutics in Boulder, CO, has been granted a U.S. patent relating to a novel method of administering paclitaxel. This patented method involves administrating smaller, more frequent doses of the drug over a shorter infusion time compared with the administration schedule currently approved by the FDA for Bristol-Meyers Squibb's paclitaxel product.
However, the patent application was based on data derived from in vitro and animal stud-ies and treatment of cancer patients using the patented method, and no controlled clinical trials have been performed.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content